

# Curriculum Vita

(Last updated in March 2021)




## Iman Karimzadeh, Pharm.D, Ph.D

✍ Associate Professor, Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran

✍ Vice Chancellor of Research and Technology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran


### ▪ Personal Records:

 **Place and Date of Birth:** Shiraz, Iran. February 21, 1984.


 **Marital Status:** Married

 **Sex:** Male

 **Nationality:** Iranian

 **Foreign Languages:** English (general competency)


 **Telephone number:** +98-71-32424128


 **Fax:** +98-71-32424126

 **Mobile number:** +98-9177017316

 **E-mail:** karimzadehiman@yahoo.com, karimzadehiman@gmail.com,

[karimzadee@sums.ac.ir](mailto:karimzadee@sums.ac.ir)

 **Address:** Shiraz, RoknAbad, Karafarin Street, Faculty of Pharmacy

 **PO Box:** 7146864685

• **ORCID ID:** <https://orcid.org/0000-0002-8956-4528>

• **Research gate address:** <https://www.researchgate.net/profile/Iman-Karimzadeh>

• **Google Scholar address:**

<https://scholar.google.com/citations?user=HY5mzkwAAAAJ&hl=en&oi=ao>

• **Scopus address:**

<https://www.scopus.com/authid/detail.uri?authorId=21742639200>



## Educational Records:

- Pharmacy Doctorate (PharmD, 2002-2009): Shiraz University of Medical Sciences, Shiraz, Iran. The PharmD thesis was under the supervision of Professors Soha Namazi, Leila Zareifar, and Ahmad Monabati.

***Title of thesis:** Evaluation the association of three genetic polymorphisms of glucocorticoid receptor gene (ER22/23EK, N363S, and BCL1) with relapse of childhood acute lymphoblastic leukemia (ALL)*

- Philosophy Doctorate (PhD, 2009-2014): Tehran University of Medical Sciences, Tehran, Iran. The PhD thesis was under the supervision of Professors Hossein Khalili and Simin Dashti-Khavidaki.

***Title of thesis:** Evaluating the effectiveness of n-acetyl cysteine in prevention of amphotericin b nephrotoxicity in hospitalized patients in Imam Khomeini hospital complex*



## Current Academic Positions:

- From November 2014 to present: In charge of educational Pharmacy Model of Shiraz Pharmacy School, Shiraz, Iran.

- From February 2015 to February 2017: In charge of Internship course of pharmacy students at educational pharmacies of Shiraz Pharmacy School, Shiraz, Iran.

- From September 2014 to present: The member of Drug and therapeutic committee of Namazi hospital, Shiraz, Iran.

- From November 2014 to April 2018: Head of Antibiotic stewardship program in Namazi hospital, Shiraz, Iran.

- From February 2016 to present: The member of university workgroup of developing guidelines for rational use of antibiotics at teaching hospitals in Shiraz, Iran.

- From November 2014 to April 2018: Head of the project of monitoring high cost medication use in Amir hospital, Shiraz, Iran.

- From January 2016 to December 2018: In charge of graduate education affairs in department of clinical pharmacy, school of pharmacy, Shiraz, Iran.

- From August 2020 to present: Vice chancellor of research and technology, school of pharmacy, Shiraz, Iran.



## Awards & Honors:

- 2005, Ranked as “2th top student in national “Comprehensive Basic Science Exam”, Iran.
- 2008, “Distinguished student” of Shiraz University of Medical Sciences, Shiraz.
- 2008, “Distinguished pharmacy student” in Iran
- 2010, Ranked as “1st top for presented poster” in the 1st Iranian Clinical Pharmacy Congress, Tehran, Iran
- 2012, Ranked as 1st top in “Comprehensive Clinical Pharmacy Board Exam”, Tehran, Iran.
- 2012, Distinguished supervisor of “13-Aban Drug and Poisoning Information Center”, Tehran, Iran.
- 2013, “Distinguished PhD Student” of Tehran University of Medical Sciences, Tehran, Iran.
- 2015, Ranked as “1st top for presented poster” in the International Congress of Quality, Safety, and Rational Use of Drugs, Mashhad, Iran.
- 2017, Ranked as “1st top for presented poster” in the 8st Iranian Clinical Pharmacy Congress, Tehran, Iran.
- 2018, “Appreciated educational process” in the 19<sup>th</sup> National Festival of Education in Medical Sciences, Tehran, Iran.
- 2018, Ranked as “top educational process” in the 11<sup>th</sup> Shahid Motahari Educational Festival of Shiraz University of Medical Sciences, Shiraz, Iran.
- 2018, “Distinguished faculty member” of School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.



## Teaching Experiences:

- Pharmacotherapy courses (including acute kidney injury, chronic kidney disease, kidney transplantation, and renal stone) for PharmD students, Shiraz Pharmacy School, Shiraz, Iran.
- Hospital pharmacy course for PharmD students, Shiraz Pharmacy School, Shiraz, Iran.
- Advanced pharmacotherapy courses (including acute kidney injury, chronic kidney disease, kidney transplantation, and renal stone) for PhD students of clinical pharmacy, Shiraz Pharmacy School, Shiraz, Iran.
- Advanced clinical pharmacokinetics (including immunosuppressive agents and dose adjustment of medication in the setting of kidney diseases, hemodialysis, continuous renal replacement therapy, and plasmapheresis) for PhD students of clinical pharmacy, Shiraz Pharmacy School, Shiraz, Iran.
- Principles of drug-drug interactions for medical students, Shiraz Pharmacy School, Shiraz, Iran.
- Continuous medical education courses for graduated physicians and pharmacists

## Major Research Interests:

- Pharmacotherapeutic aspects of acute kidney injury, chronic kidney disease, dialysis, and kidney transplantation
- Biomarkers of kidney function in acute kidney injury
- Prevention of drug-induced kidney injury
- Pharmacogenetics in the setting of kidney diseases and transplantation
- Pharmacovigilance

## Major Research Skills:

- Designing and performing clinical trials
- Designing and performing pharmacogenetics studies using PCR-RFLP technique
- Designing and performing pharmacovigilance studies
- Writing narrative as well as systematic reviews
- Performing statistical analyses by the SPSS software

## Research Publications:

- 1- Namazi S, Borhani Haghighi A, Karimzadeh I. **Is oral azithromycin effective for the treatment of phenytoin-induced gingival overgrowth in epileptic patients?** Med Hypotheses. 2007;69(5):1159-60.
- 2- Namazi S, Karimzadeh I, Fanni H. **Immediate reaction to a single dose of cephalexin in a 16-year-old girl without past allergic history to penicillins.** EJHP Science. 2007;13(1): 17-21.
- 3- Karimzadeh I, Namazi S, Vessal G. **Erythropoietin as a neuroprotectant: Does phenytoin exert its neuroprotective functions through stimulation of erythropoietin production?** Med Hypotheses Res. 2009;5:79-91.
- 4- Namazi S, Zareifar S, Monabati A, Ansari S, Karimzadeh I. **Evaluating the effect of 3 glucocorticoid receptor gene polymorphisms on risk of relapse in 100 Iranian children with acute lymphoblastic leukemia: a case-control study.** Clin Ther. 2011;33(3):280-90.
- 5- Namazi S, Borhani-Haghighi A, Karimzadeh I. **Adverse reactions to antiepileptic drugs in epileptic outpatients: a cross-sectional study in Iran.** Clin Neuropharmacol. 2011;34(2):79-83.
- 6- Karimzadeh I, Namazi S, Shalviri G, Gholami K. **Cardiovascular drug adverse reactions in hospitalized patients in cardiac care unit.** Afr J Pharm Pharmacol. 2011;5(4):493-9.
- 7- Namazi S, Karimzadeh I. **Drug utilization evaluation of unfractionated heparin in a cardiac care unit in Iran.** Journal of Pharmacy Research. 2011;4(5):1470-2.

- 8- Namazi S, Sagheb MM, Karimzadeh I. **Adverse reactions of immunosuppressive drugs in Iranian adult kidney transplant recipients.** Exp Clin Transplant. 2012;10(3):224-31.
- 9- Khalili H, Dashti-Khavidaki S, Karimzadeh I, Jafari S, Abdollahi A, Shahidi MR, Jahangard-Rafsanjani Z, Entezari-Maleki T. **Changes in 4-year antimicrobial resistance pattern of gram-positive bacteria at the main referral teaching hospital, Tehran, Iran.** Acta Med Iran. 2012;50(7):493-504.
- 10- Farsaie S, Khalili H, Karimzadeh I, Dashti-Khavidaki S. **An old drug for a new application: potential benefits of sildenafil in wound healing.** J Pharm Pharm Sci. 2012;15(4):483-98.
- 11- Karimzadeh I, Farsaei S, Khalili H, Dashti-Khavidaki S. **Are salt loading and prolonging infusion period effective in prevention of amphotericin B-induced nephrotoxicity?** Expert Opin Drug Saf. 2012;11(6):969-83.
- 12- Honarbakhsh N, Rouini MR, Lesan-Pezeshki M, Javadi MR, Karimzadeh I, Mohebbi N, Gholami K. **Mycophenolic Acid pharmacokinetics early after kidney transplant.** Exp Clin Transplant. 2013;11(2):112-7.
- 13- Khalili H, Karimzadeh I, Mirzabeigi P, Dashti-Khavidaki S. **Evaluation of clinical pharmacist's interventions in an infectious diseases ward and impact on patient's direct medication cost.** Eur J Intern Med. 2013;24(3):227-33.
- 14- Hatamkhani S, Karimzadeh I, Elyasi S, Farsaie S, Khalili H. **Carnitine and sepsis: a review of an old clinical dilemma.** J Pharm Pharm Sci. 2013;16(3):414-23.
- 15- Hadjibabaie M, Badri S, Ataei S, Moslehi AH, Karimzadeh I, Ghavamzadeh A. **Potential drug-drug interactions at a referral hematology-oncology ward in Iran: a cross-sectional study.** Cancer Chemother Pharmacol. 2013;71(6):1619-27.
- 16- Ravi S, Nasiri Toosi M, Karimzadeh I, Ahadi-Barzoki M, Khalili H. **Adherence to chronic hepatitis C treatment regimen: first report from a referral center in Iran.** Hepat Mon. 2013;13(6):e11038.
- 17- Karimzadeh I, Khalili H, Farsaei S, Dashti-Khavidaki S, Sagheb MM. **Role of diuretics and lipid formulations in the prevention of amphotericin B-induced nephrotoxicity.** Eur J Clin Pharmacol. 2013;69(7):1351-68.
- 18- Farsaei S, Khalili H, Farboud ES, Karimzadeh I, Beigmohammadi MT. **Efficacy of topical atorvastatin for the treatment of pressure ulcers: a randomized clinical trial.** Pharmacotherapy. 2014;34(1):19-27.
- 19- Hatamkhani S, Khalili H, Karimzadeh I, Abdollahi A, Jafari S, Khazaeipour Z. **Carnitine deficiency and its possible risk factors in TB patients: first report.** Immunotherapy. 2013;5(9):945-53.
- 20- Gholami K, Rouini MR, Mohebbi N, Karimzadeh I, Ahadi-Barzoki M, Lesan-Pezeshki M, Rezaee S. **Pharmacokinetic study of mycophenolic acid in Iranian kidney transplant patients.** J Pharm Care. 2013;1(1):13-8.

- 21- Karimzadeh I, Sadeghi K. **Introduction to prominent journals publishing pharmaceutical care issues.** J Pharm Care. 2013;1(3):119-24.
- 22- Baniasadi S, Habibi M, Haghgoo R, Karimi Gamishan M, Dabaghzadeh F, Farasatinasab M, Farsaei S, Gharekhani A, Kafi H, Karimzadeh I, Kharazmkia A, Najmeddin F, Nikvarz N, Oghazian MB, Rezaee H, Sadeghi K, Tafazzoli A, Shahsavari N, Fahimi F. **Increasing the number of adverse drug reactions reporting: the role of clinical pharmacy residents.** Iran J Pharm Res. 2014;13(1):291-7.
- 23- Ravi S, Nasiri-Toosi M, Karimzadeh I, Khalili H, Ahadi-Barzoki M, Dashti-Khavidaki S. **Pattern and associated factors of anti-hepatitis C virus treatment-induced adverse reactions.** Expert Opin Drug Saf. 2014;13(3):277-86.
- 24- Farsaei S, Karimzadeh I, Elyasi S, Hatamkhani S, Khalili H. **Glycemic control in the infectious diseases ward; role of clinical pharmacist interventions.** J Infect Dev Ctries. 2014;8(4):480-9.
- 25- Karimzadeh I, Khalili H, Dashti-Khavidaki S, Sharifian R, Abdollahi A, Hasibi M, Khazaeipour Z, Farsaei S. **N-acetyl cysteine in prevention of amphotericin- induced electrolytes imbalances: a randomized, double-blinded, placebo-controlled, clinical trial.** Eur J Clin Pharmacol. 2014;70(4):399-408.
- 26- Hatamkhani S, Khalili H, Karimzadeh I, Dashti-Khavidaki S, Abdollahi A, Jafari S. **Carnitine for prevention of antituberculosis drug-induced hepatotoxicity: a randomized, clinical trial.** J Gastroenterol Hepatol. 2014;29(5):997-1004.
- 27- Sagheb MM, Namazi S, Geramizadeh B, Karimzadeh A, Oghazian MB, Karimzadeh I. **Serum cystatin C as a marker of renal function in critically ill patients with normal serum creatinine.** Nephrourol Mon. 2014;6(2):e15224.
- 28- Karimzadeh I. **The Annals of Pharmacotherapy Evolutionary Trend From the Past to Present.** J Pharm Care. 2014;2(1):45-7.
- 29- Mapar MA, Ranjbari N, Afshar N, Karimzadeh I, Karimzadeh A. **Severely disfiguring multiple familial trichoepitheliomas with basal cell carcinoma.** Indian J Dermatol Venereol Leprol. 2014;80(4):349-52.
- 30- Shohrati M, Karimzadeh I, Saburi A, Khalili H, Ghanei M. **The role of N-acetylcysteine in the management of acute and chronic pulmonary complications of sulfur mustard: a literature review.** Inhal Toxicol. 2014;26(9):507-23.
- 31- Gholaminezhad S, Hadjibabaie M, Gholami K, Javadi MR, Radfar M, Karimzadeh I, Ghavamzadeh A. **Pattern and associated factors of potential drug-drug interactions in both pre- and early post-hematopoietic stem cell transplantation stages at a referral center in the Middle East.** Ann Hematol. 2014;93(11):1913-22.

- 32- Entezari-Maleki T, Taraz M, Javadi MR, Hajimiri MH, Eslami K, Karimzadeh I, Esmaeili M, Gholami K. **A two-year utilization of the pharmacist-operated drug information center in Iran.** J Res Pharm Pract. 2014;3(4):117-22.
- 33- Khajehpiri Z, Mahmoudi-Gharaei J, Faghihi T, Karimzadeh I, Khalili H, Mohammadi M. **Adverse reactions of Methylphenidate in children with attention deficit-hyperactivity disorder: Report from a referral center.** J Res Pharm Pract. 2014;3(4):130-6.
- 34- Farhoudi M, Khalili H, Karimzadeh I, Abbasian L. **Associated factors of drug-drug interactions of highly active antiretroviral therapy: report from a referral center.** Expert Opin Drug Metab Toxicol. 2015;11(4):471-9.
- 35- Entezari-Maleki T, Khalili H, Karimzadeh I, Jafari S. **Approach to Anemia in Hospitalized Patients with Infectious Diseases; Is it Appropriate?** Iran J Pharm Res. 2015;14(2):487-93.
- 36- Karimzadeh I, Khalili H, Sagheb MM, Farsaei S. **A double-blinded, placebo-controlled, multicenter clinical trial of N-acetylcysteine for preventing amphotericin B-induced nephrotoxicity.** Expert Opin Drug Metab Toxicol. 2015;11(9):1345-55.
- 37- Karimzadeh I, Khalili H, Sagheb MM, **Preventing or attenuating amphotericin B nephrotoxicity with dopamine receptor agonists: a literature review.** Trends in Pharmaceutical Sciences 2015;1(3):129-38.
- 38- Karimzadeh I, Namazi S; Borhani-Haghighi A, Khosropanah H. **Phenytoin-Induced Gingival Over Growth: A Review.** Soc Pharm J. 2015;1(1):e827.
- 39- Heydaria B, Khalili H, Karimzadeh I, Emadi-Kochak H. **Clinical, paraclinical, and antimicrobial resistance features of community-acquired acute bacterial meningitis at a large infectious diseases ward in Tehran, Iran.** Iran J Pharm Res. 2016;15 (1):347-54.
- 40- Karimzadeh I, Khalili H. **Comparison between a serum creatinine-and a cystatin C-based glomerular filtration rate equation in patients receiving amphotericin B.** Daru. 2016 Jun 6;24(1):16.
- 41- Karimzadeh I, Heydari M, Mani Ramzi M, Sagheb MM. **Frequency and associated factors of amphotericin B nephrotoxicity in hospitalized patients in hematology-oncology wards in the southwest of Iran.** Nephrourol Mon. 2016 September; 8(5):e39581.
- 42- Karimzadeh I, Haghighati G, Ramzi M, Sagheb MM, Zomorodian K. **Electrolyte disorders during vancomycin treatment in hospitalized patients at hematology-oncology wards of Namazi hospital in Shiraz.** Trends in Pharmaceutical Sciences. 2016;2(3):223-8.
- 43- Karimzadeh I, Mirzaee M, Sadeghimanesh N, Sagheb MM. **Antimicrobial resistance pattern of Gram-positive bacteria during three consecutive years at the nephrology ward of a tertiary referral hospital in Shiraz, Southwest Iran.** J Res Pharm Pract. 2016;5:238-47.
- 44- Heydari B, Karimzadeh I, Khalili H, Shojaei E, Ebrahimi A. **Infective endocarditis; report from a main referral teaching hospital in Iran.** Iran J Pharm Res. 2017;16(1):390-8.

- 45- [Karimzadeh J](#), Haghghati G, Ramzi M, Sagheb MM, Zomorodian K. **Assessing the Epidemiology of Nephrotoxicity and the Role of Urinary Kidney Injury Molecule 1 as a Biomarker of Renal Function in Hematologic-Oncologic Patients Under Vancomycin Treatment in Shiraz, Iran.** Iran Red Crescent Med J. 2017;19(3):e40858.
- 46- [Karimzadeh J](#), Khalili H. **The potential effects of non-renal factors, glucocorticoid treatment and hematological malignancies, on serum cystatin C level.** Trends in Pharmaceutical Sciences. 2017; 3(1):1-6.
- 47- Heydari B, Khalili H, Beigmohammadi MT, Abdollahi A, [Karimzadeh J](#). **Effects of atorvastatin on biomarkers of acute kidney injury in amikacin recipients: A pilot, randomized, placebo-controlled, clinical trial.** J Res Med Sci. 2017;22:39.
- 48- [Karimzadeh J](#), Sadeghimanesh N, Mirzaee M, Sagheb MM. **Evaluating the resistance pattern of gram negative bacteria during three years at the nephrology ward of a referral hospital in southwest of Iran.** J Nephropathol. 2017;6(3):210-9.
- 49- [Karimzadeh J](#), Heydari M, Ramzi M, Sagheb MM, Zomorodian K. **Urinary Neutrophil Gelatinase-associated Lipocalin as a Biomarker of Kidney Injury in Hematologic-Oncologic Patients Receiving Amphotericin B.** Iran J Kidney Dis. 2017;11(3):201-8.
- 50- Vazin A, [Karimzadeh J](#), Zand A, Hatami-Mazinani N, Firouzabadi D. **Evaluating Adherence of Health-Care Team to Standard Guideline of Colistin Use at Intensive Care Units of a Referral Hospital in Shiraz, Southwest of Iran.** Adv Pharm Bull. 2017 Sep;7(3):391-397.
- 51- Roodaki M, Abolhassanzadeh Z, [Karimzadeh J](#), Faridi P. **Hot and cold: An old theory with modern applications.** Trends in Pharmaceutical Sciences. 2018: 4(1):59-82.
- 52- [Karimzadeh J](#), Namazi MR, Karimzadeh A. **Trichoepithelioma: A Comprehensive Review.** Acta Dermatovenerol Croat. 2018;26(2):162-165.
- 53- Davani-Davari D, [Karimzadeh J](#), Sagheb MM, Khalili H. **The Renal Safety of L-Carnitine, L-Arginine, and Glutamine in Athletes and Bodybuilders.** J Ren Nutr. 2019;29(3):221-234.
- 54- Vazin A, [Karimzadeh J](#), Karamikhah R, Oveisi Z, Mohseni S, Keykhaee M, Roshanfard F, Sabet E, Zargari-Samadnejad A. **Clinical and economic impacts of guideline implementation by the pharmaceutical care unit for high cost medications in a referral teaching hospital.** BMC Health Serv Res. 2018 Oct 24;18(1):815.
- 55- Davani-Davari D, [Karimzadeh J](#), Ezzatzadegan-Jahromi S, Sagheb MM. **Potential Adverse Effects of Creatine Supplement on the Kidney in Athletes and Bodybuilders.** Iran J Kidney Dis. 2018;12(5):253-260.
- 56- Davani-Davari D, Negahdaripour M, [Karimzadeh J](#), Seifan M, Mohkam M, Masoumi SJ, Berenjian A, Ghasemi Y. **Prebiotics: Definition, Types, Sources, Mechanisms, and Clinical Applications.** Foods. 2019 Mar 9;8(3):1-27.



- 57- Davani-Davari D, [Karimzadeh I](#), Khalili H. **The potential effects of anabolic-androgenic steroids and growth hormone as commonly used sport supplements on the kidney: a systematic review.** BMC Nephrology. 2019;20:198.
- 58- Davani-Davari D, [Karimzadeh I](#), Sagheb MM, Khalili H. **The Renal Safety of L-Carnitine, L-Arginine, and Glutamine in Athletes and Bodybuilders.** J Ren Nutr. 2019; 29(3):221-234.
- 59- Moradi O, [Karimzadeh I](#), Davani-Davari D, Shafiekhani M, Sagheb MM. **Pattern and associated factors of adherence to immunosuppressive medications in kidney transplant recipients at a referral center in Iran.** Patient Preference and Adherence 2019;13:729-738.
- 60- Noormandi A, [Karimzadeh I](#), Mirjalili M, Khalili H. **Clinical and economic impacts of clinical pharmacists' interventions in Iran: a systematic review.** DARU Journal of Pharmaceutical Sciences 2019;27:361-378.
- 61- Davani-Davari D, Negahdaripour M, [Karimzadeh I](#), Seifan M, Mohkam M, Masoumi SJ, Berenjian A, Ghasemi Y. **Prebiotics: Definition, Types, Sources, Mechanisms, and Clinical Applications.** Foods. 2019 Mar 9;8(3):92.
- 62- Mahi-Birjand M, Yaghoubi S, Abdollahpour-Alitappeh M, Keshtkaran Z, Bagheri N, Pirouzi A, Khatami M, Sineh Sepehr K, Peymani P, [Karimzadeh I](#). **Protective effects of pharmacological agents against aminoglycoside-induced nephrotoxicity: A systematic review.** Expert Opin Drug Saf. 2020 Feb;19(2):167-186.
- 63- Shafiekhani M, [Karimzadeh I](#), Nikeghbalian S, Firoozifar M, Pouladfar G, Vazin A. **Comparison of Ceftizoxime Plus Ampicillin-Sulbactam versus Gentamicin Plus Ampicillin-Sulbactam in the Prevention of Post-Transplant Early Bacterial Infections in Liver Transplant Recipients: A Randomized Controlled Trial.** Infect Drug Resist. 2020 Jan 8;13:89-98.
- 64- Kordzadeh-Kermani E, Khalili H, [Karimzadeh I](#), Salehi M. **Prevention Strategies to Minimize the Infection Risk Associated with Biologic and Targeted Immunomodulators.** Infect Drug Resist. 2020 Feb 18;13:513-532.
- 65- Zarei L, [Karimzadeh I](#), Moradi N, Peymani P, Asadi S, Babar ZU. **Affordability Assessment from a Static to Dynamic Concept: A Scenario-Based Assessment of Cardiovascular Medicines.** Int J Environ Res Public Health. 2020 Mar 5;17(5):1710.
- 66- Bagheri Z, Labbani-Motlagh Z, Mirjalili M, [Karimzadeh I](#), Khalili H. **Types and outcomes of cytopenia in critically ill patients.** J Comp Eff Res. 2020 Jun;9(9):627-637.
- 67- MohammadSadeghi A, [Karimzadeh I](#), Bagheri Lankarani K, Banakar M. **Pharmacotherapy for reducing saliva and droplet production in airborne procedures may help to decrease the COVID-19 transmission: A hypothesis.** Med Hypotheses. 2020 Jun 1;144:109874.
- 68- Asadi-Pooya AA, Attar A, Moghadami M, [Karimzadeh I](#). **Management of COVID-19 in people with epilepsy: drug considerations.** Neurol Sci. 2020 Aug;41(8):2005-2011.

- 69- Ghasemiyeh P, Borhani-Haghighi A, Karimzadeh I, Mohammadi-Samani S, Vazin A, Safari A, Qureshi AI. **Major Neurologic Adverse Drug Reactions, Potential Drug-Drug Interactions and Pharmacokinetic Aspects of Drugs Used in COVID-19 Patients with Stroke: A Narrative Review.** Ther Clin Risk Manag. 2020 Jun 30;16:595-605.
- 70- Forouzani-Haghighi B, Karimzadeh I. **Isotretinoin and the Kidney: Opportunities and Threats.** Clin Cosmet Investig Dermatol. 2020 Jul 28;13:485-494.
- 71- Kordzadeh-Kermani E, Khalili H, Karimzadeh I. **Pathogenesis, clinical manifestations and complications of coronavirus disease 2019 (COVID-19).** Future Microbiol. 2020 Sep;15:1287-1305.
- 72- Zare M, Zarei L, Afifi S, Karimzadeh I, Ghaemini M, Peiravian F, Salehi-Marzijarani M, Lankarani KB, Peymani P. **Evaluating Pharmacist's Patient Care Process in Shiraz, using a newly-validated questionnaire: The First Report from Iran.** Acta Biomed. 2020 Sep 7;91(3):e2020059.
- 73- Mahi-Birjand M, Karimzadeh I, Zarban A, Abdollahpour-Alitappeh M, Seyed Alireza Saadatjoo SA, Ziaee M. **Protective effects of silymarin on gentamicin-induced nephrotoxicity in infectious patients: A randomized double blinded placebo-controlled clinical trial.** Pharm Sci. 2020;26(3): 287-295.
- 74- Vazin A, Malek M, Karimzadeh I. **Evaluation of colistin nephrotoxicity and urinary level of kidney injury molecule-1 in hospitalized adult ICU patients.** J Renal Inj Prev. 2020; 9(2): e13.
- 75- Zare M, Afifi S, Karimzadeh I, Salehi-Marzijarani M, Zarei L, Ghazipour G, et al. **A population-based study on patients complaining regarding community pharmacies services.** J Res Pharm Pract 2020;9:88-93.
- 76- Moradi O, Karimzadeh I, Davani-Davari D, Shafiekhani M, Sagheb MM, Raees-Jalali GA. **Drug-Drug Interactions among Kidney Transplant Recipients in The Outpatient Setting.** Int J Organ Transplant Med. 2020;11(4):185-195.
- 77- Karimzadeh I, Jafari M, Davani-Davari D, Ramzi M. **The Pattern of Cyclosporine Nephrotoxicity and Urinary Kidney Injury Molecule 1 in Allogenic Hematopoietic Stem Cell Transplant Patients.** Exp Clin Transplant. 2020 Nov 27.
- 78- Roostaei Firozabad A, Meybodi ZA, Mousavinasab SR, Sahebnasagh A, Jelodar MG, Karimzadeh I, Habtemariam S, Saghafi F. **Efficacy and safety of Levamisole treatment in clinical presentations of non-hospitalized patients with COVID-19: a double-blind, randomized, controlled trial.** BMC Infect Dis. 2021 Mar 24;21(1):297.
- 79- Karamikhah R, Azarpira N, Zareifar S, Dehshahri A, Namazi S, Anbardar MH, Karimzadeh I. **The Effects of Three ABCG2 Polymorphisms on Outcome of Central Nervous System Relapses in Iranian Children With Acute Lymphoblastic Leukemia Receiving High Dose Methotrexate.** Acta Medica Iranica. 2021; 59(3):133-141.

- 80- Mousavinasab SR, Akhoundi-Meybodi Z, Mahmoudi L, Karimzadeh I. **A randomized double-blinded placebo-controlled clinical trial on protective effects of pentoxifylline on gentamicin nephrotoxicity in infectious patients.** Clin Exp Nephrol. 2021 (Corrected paper proof).
- 81- Shaghayegh Mottaghi S, Sagheb MM, Azarpira N, Abdizadeh F, Faeghi R, Karimzadeh I. **Association between the Three Polymorphisms of the Glucocorticoid Receptor Gene and the Early Clinical Outcome in Kidney Transplantation Patients.** Iran J Med Sci. 2021 (Articles in Press).



### Congress presentations

- 1- **The evaluation of adverse drug reactions of antiepileptic drugs in epileptic out-patients.** 35th European Symposium on Clinical Pharmacy, 2006, Vienna.
- 2- **Evaluation of adverse drug reactions of immunosuppressant drugs in kidney transplant patients in Namazi transplant center, Shiraz, Iran.** 7th World Congress of Nephrology, 2007, Rio de Janeiro.
- 3- **Evaluation of adverse drug reactions of cardiovascular medications reported by nursing staff in Namazi hospital CCU, Shiraz, Iran.** 9th Iranian Congress of Toxicology, 2007, Shiraz.
- 4- **Drug utilization evaluation of amikacin in the internal medicine ward of Namazi hospital, Shiraz, Iran.** 1th Iranian Congress of Clinical Microbiology, 2007, Shiraz.
- 5- **Frequency of antiepileptic adverse drug reactions in an out-patient epilepsy clinic in the south of Iran: a cross-sectional study.** 4th Epilepsy Congress, 2007, Tehran.
- 6- **Drug utilization evaluation of unfractionated heparin in Namazi hospital CCU, Shiraz, Iran.** 12th Iranian Pharmaceutical Sciences Congress, 2010, Zanjan.
- 7- **Evaluating serum cystatin C as a marker of renal function in critically ill patients.** 2nd Iranian Clinical Pharmacy Congress, 2011, Tehran.
- 8- **Evaluating antimicrobial resistance pattern of gram-positive bacteria at infectious diseases ward of Imam Khomeini Hospital from 2007 to 2010.** 20th Iranian Congress on Infectious Diseases and Tropical Medicine, 2011, Tehran.
- 9- **The impact of 3 glucocorticoid receptor gene polymorphisms on risk of relapse in childhood acute lymphoblastic leukemia (ALL) in Iranian population.** 1st Biotechnology World Congress, 2012, Dubai.
- 10- **Clinical pharmacists' interventions to improve the glycemic control in patients with infectious diseases.** 4th Iranian Clinical Pharmacy Congress, 2013, Tehran.
- 11- **An overview of gingival overgrowth caused by phenytoin.** 11th international Congress on Epilepsy, 2015, Tehran.
- 12- **A double-blinded, placebo-controlled clinical trial of N-acetyl cysteine for preventing amphotericin b nephrotoxicity.** International Congress of Nephrology and Urology, 2015, Tehran.

- 13- **Improving the utilization pattern and decreasing the direct cost of albumin by pharmacist interventions at an oncology hospital in Iran.** 5th Annual European Pharma Congress, 2016, Germany.
- 14- **Guideline implementation by pharmaceutical care unit for three highly cost medications during two consecutive years at Namazi hospital in Shiraz.** 20th Iranian Pharmacy Students Seminar, 2017, Tehran.
- 15- **Evaluating urinary neutrophil gelatinase-associated lipocalin as a biomarker of renal function in hematologic-oncologic patients receiving amphotericin B.** 2nd International Congress on Hematological Disorders, 2017, Shiraz.
- 16- **Implementing Intravenous Pantoprazole Guideline by Pharmacists at an Oncology Hospital in Southwest of Iran.** 8th Iranian Clinical Pharmacy Congress, 2017, Tehran.
- 17- **Evaluating nephrotoxicity of vancomycin and the role of urinary kidney injury molecule-1 in hematologic-oncologic patients under vancomycin treatment in Namazi hospital in Shiraz.** 8th Iranian Clinical Pharmacy Congress, 2017, Tehran.
- 18- **Impact of albumin and intravenous pantoprazole use guidelines in two intensive care units of a teaching hospital.** 8th Iranian Clinical Pharmacy Congress, 2017, Tehran.
- 19- **Aminoglycosides: Once-daily or multiple-daily dosing? An update systematic review of randomized trials on the toxicity and efficacy.** 21st Iranian Pharmacy Students Seminar, 2017, Ahvaz.
- 20- **Protective Effects of Pharmacological Agents Against Nephrotoxicity of Aminoglycosides: An Overview.** 9th Iranian Clinical Pharmacy Congress, 2018, Tehran.
- 21- **Medication Reconciliation in Patients Admitted to Namazi Hospital within a Six-Month Period.** 9th Iranian Clinical Pharmacy Congress, 2018, Tehran.
- 22- **N-acetylcysteine for the management of acute and chronic pulmonary complications of sulfur mustard; from bench to bedside.** 2th Pharmacy Updates, 2019, Tehran.
- 23- **Evaluation of consumption rate and direct cost of parenteral antibiotics before and after Health Revolution Program at the Namazi hospital in Shiraz.** 2th Pharmacy Updates, 2019, Tehran.
- 24- **Evaluation of non-prescription and over-the-counter drug therapy pattern in Shiraz pharmacies.** 22th Iranian Pharmacy Students Seminar, 2019, Zanjan.
- 25- **Evaluating the Association Between Two Polymorphisms of Glucocorticoid Receptor Gene (BclI & N363S) and 1-Year Clinical Outcome in Kidney Transplant Patients in Shiraz.** 10th Iranian Clinical Pharmacy Congress, 2019, Tehran.
- 26- **Drug utilization evaluation of Rivaroxaban as a direct oral anticoagulant based on the standard guidelines in Shiraz.** 10th Iranian Clinical Pharmacy Congress, 2019, Tehran.

27- **Drug-drug interactions among kidney transplant recipients in the outpatient setting.** 10th Iranian Clinical Pharmacy Congress, 2019, Tehran.

28- **Pattern and Associated Factors of Adherence to Immunosuppressive Medications in Kidney Transplant Recipients at A Referral Center in Iran.** 10th Iranian Clinical Pharmacy Congress, 2019, Tehran.

29- **Evaluating One Polymorphism of Glucocorticoid Receptor Gene (ER22/23EK) and 1-Year Clinical Outcome in Kidney Transplant Patients in Shiraz.** 16th Iranian Pharmaceutical Sciences Congress, 2019, Kermanshah.

30- **Evaluating the usage pattern of high-cost antibiotics before and after an antibiotic stewardship program at Namazi hospital in Shiraz.** 16th Iranian Pharmaceutical Sciences Congress, 2019, Kermanshah.



### **Written or Translated Books**

- 1- Applied Handbook of Injectable Drugs (3th edition). Tehran, 2016 (Written-In Persian).
- 2- Pharmacotherapy Clinical Guidelines. Tehran, 2012 (Written-In Persian).
- 3- Comprehensive Textbook of Therapeutics (2th edition), Tehran, 2017 (Written-In Persian).
- 4- Molecular Farming, Tabriz, 2013 (Translated-In Persian).



### **Thesis Supervisor/Advisor**

- 1- Dr. Mojtaba Shafiekhani (PhD), 2019: Advisor. **Comparison of efficacy of two different antibiotic prophylactic regimens for bacterial infections in liver transplant recipients**
- 2- Dr. Raziheh Karamikhah (PhD), 2020: Supervisor. **Evaluation of The Effects of Three ABCG2 Polymorphisms (G34A, C376T, And C421A) On Outcome of Central Nervous System Relapses in Iranian Children with Acute Lymphoblastic Leukemia Receiving High Dose Methotrexate.**
- 3- Dr. Motahareh Mahi-Birjand (PhD), 2020: Supervisor. **Evaluating the effectiveness of Silymarin on the prevention of gentamicin nephrotoxicity in hospitalized patients at Imam Reza & Vali-Asr hospitals in Birjand.**
- 4- Dr. Seyed Ruhollah Mousavinasab (PhD), 2021: Supervisor. **Evaluating the effectiveness of Pentoxifylline on the prevention of gentamicin nephrotoxicity in hospitalized patients in Shiraz.**
- 5- Atiyeh Zand (PharmD), 2015: Advisor. **Evaluating Adherence of Health-Care Team to Standard Guideline of Colistin Use at Intensive Care Units of a Referral Hospital in Namazi Shiraz.**
- 6- Omid Moradi (PharmD), 2016: Supervisor. **Evaluating the pattern and associated factors of adherence to immunosuppressive regimen and potential drug-drug interactions in kidney transplant recipients in Shiraz.**

- 7- Ammar Mohammadi (PharmD), 2017: Supervisor. **Investigation of patients' rights and its disturbing factors from viewpoints of patients' and Shiraz University of Medical Sciences pharmacy students' in 2016.**
- 8- Maryam Roodaki (PharmD), 2017: Supervisor. **Investigating Blood electrolyte changes with the use of hot traditional medicine in healthy people**
- 9- Nafiseh Jamalzadeh (PharmD), 2017: Advisor. **The pattern of Complementary and Alternative Medicine use and its relevant potential drug interactions in cancer patients**
- 10- Nikoo Sakhajoo (PharmD), 2018: Supervisor. **Evaluation of usage status and direct cost of parenteral antibiotics before and after Health Revolution Program at Namazi hospital in Shiraz.**
- 11- Marziyeh Heydari (PharmD), 2018: Supervisor. **Evaluating nephrotoxicity of amphotericin b and urinary level of neutrophil gelatinase-associated lipocalin trend in hospitalized adult patients in hematology-oncology wards of Namazi hospital from August 2017 to April 2018.**
- 12- Ghazaleh Haghighati (PharmD), 2018: Supervisor. **Evaluating nephrotoxicity of vancomycin and urinary Kidney Injury Molecule-1 level trend in hospitalized adult patients in hematology-oncology wards of Namazi hospital from August 2017 to April 2018.**
- 13- Nahid Jalali (PharmD), 2018: Supervisor. **A cost utility analysis of different medicinal regimens in patients with chronic Hepatitis C virus genotype 1 infection.**
- 14- Atefeh Jalali (PharmD), 2019: Supervisor. **Drug utilization evaluation of direct oral anticoagulants including dabigatran and rivaroxaban based on the standard guidelines in hospitalized patients at the Namazi hospital in Shiraz.**
- 15- Mahtab Jafari (PharmD), 2019: Supervisor. **Evaluating nephrotoxicity of cyclosporine and urinary level of kidney injury molecule-1 trend in hospitalized adult patients undergone allogeneic hematopoietic stem cell transplantation in Namazi hospital.**
- 16- Faezeh Abdizadeh (PharmD), 2019: Supervisor. **Evaluating the association between two polymorphisms of glucocorticoid receptor gene (BclI & N363S) and 1-year clinical outcome in kidney transplant patients in Shiraz.**
- 17- Romina Faeghi (PharmD), 2019: Supervisor. **Evaluating the association between one polymorphism of glucocorticoid receptor gene (ER22/23EK) and 1-year clinical outcome in kidney transplant patients in Shiraz.**
- 18- Seyedeh Shima Ghetmiri (PharmD), 2019: Supervisor. **Evaluation of usage status of antibiotics before and after infection specialist interference Program at Namazi hospital in Shiraz**
- 19- Elham Zarei (PharmD), 2019: Supervisor. **National Essential Medicines List: Selection of Essential Anti-diabetic (Hypoglycemic) Medicines.**

20- Mohammad Bazyar (PharmD), 2020: Supervisor. **Cost-effectiveness analysis of Triptorelin, Goserelin and Leuprolide in the treatment of Patients with prostate cancer referring to Shiraz Shahid Motahari and Shahid Faghihi Clinics, 2019.**

21- Ramin Ansari (PharmD), 2020: Supervisor. **Library study of kidney stone dissolving medicaments in Persian medicine and evaluation of a related multi-ingredient formulation in dissolving calcium kidney stones; a double-blind randomized clinical trial**

22- Maryam Farsi (PharmD), 2021: Supervisor. **Evaluating the pattern of catheter associated infections in hemodialysis patients in Namazi hospital in 1399.**